Allos Therapeutics Inc - Post-Effective Amendment to an S-8 filing (S-8 POS)
25 6월 2008 - 4:52AM
Edgar (US Regulatory)
As filed
with the Securities and Exchange Commission on June 24, 2008
Registration
No. 333-134654
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
POST-EFFECTIVE
AMENDMENT NO. 1
TO
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
ALLOS
THERAPEUTICS, INC.
(Exact name of
registrant as specified in its charter)
Delaware
|
|
|
|
54-1655029
|
(State of
Incorporation)
|
|
|
|
(I.R.S. Employer
Identification No.)
|
11080 CirclePoint Road, Suite 200
Westminster, Colorado 80020
(Address of principal executive offices)
2006 Inducement Award Plan
(Full title of the plan)
Paul L. Berns
President and Chief Executive Officer
Allos Therapeutics, Inc.
11080 CirclePoint Road, Suite 200
Westminster, Colorado 80020
(303) 426-6262
(Name, address, including zip code, and telephone
number, including area code, of agent for service)
Copies to:
James C. T. Linfield, Esq.
Brent D. Fassett, Esq.
COOLEY GODWARD KRONISH LLP
380 Interlocken Crescent, Suite 900
Broomfield, Colorado 80021
(720) 566-4000
Indicate by check
mark whether the registrant is a large accelerated filer, an accelerated filer,
a non-accelerated filer, or a smaller reporting company. See definitions of large
accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2
of the Exchange Act. (Check one):
Large
accelerated filer
o
|
Accelerated
filer
x
|
Non-accelerated
filer
o
|
Smaller
reporting company
o
|
|
|
|
(Do not check if a smaller
|
|
|
|
|
|
reporting company)
|
|
|
|
|
|
|
|
|
DEREGISTRATION OF UNSOLD SECURITIES
This Post-Effective
Amendment No. 1 to Form S-8 Registration Statement relates to the
Registration Statement on Form S-8 (File No. 333-134654) (the Registration
Statement) of Allos Therapeutics, Inc. (the Company) pertaining to
1,500,000 shares of the Companys common stock, par value $0.001 per share,
which was filed with the Securities and Exchange Commission and became
effective on June 1, 2006. The
Registration Statement registered 1,500,000 shares of common stock for sale
pursuant to the Companys 2006 Inducement Award Plan (the 2006 Plan).
On June 24, 2008
(the Effective Date), the stockholders of the Company approved the Companys
2008 Equity Incentive Plan (the 2008 Plan).
The 2008 Plan is intended as the successor to and continuation of the
2006 Plan. As of the Effective Date of
the 2008 Plan, all shares remaining available for issuance under the 2006 Plan
became available for issuance under the 2008 Plan and all outstanding stock
awards granted under the 2006 Plan were deemed granted pursuant to the 2008
Plan, but remain subject to the terms of the 2006 Plan. As of the Effective Date, no additional stock
awards will be granted under the 2006 Plan.
The Company intends to file a new Form S-8 Registration Statement
pertaining to the 2008 Plan.
Subject to the foregoing,
and in accordance with an undertaking made by the Company in the Registration
Statement to remove from registration, by means of a post-effective amendment,
any of the securities registered under the Registration Statement that remain
unsold at the termination of the offering, the Company hereby removes from
registration the securities of the Company registered but unsold under the
Registration Statement.
2
SIGNATURES
Pursuant to the
requirements of the Securities Act of 1933, as amended, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-8 and has duly caused this Post-Effective
Amendment No. 1 to Registration Statement to be signed on its behalf by
the undersigned, thereunto duly authorized, in the City of Westminster, State
of Colorado, on June 24, 2008.
|
ALLOS
THERAPEUTICS, INC.
|
|
|
|
|
|
By:
|
/s/ Paul L. Berns
|
|
Paul L. Berns
|
|
President and Chief Executive Officer
|
Pursuant to the
requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1
to Registration Statement has been signed by the following persons in the
capacities and on the dates indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Stephen J. Hoffman
|
|
Chairman of Board of
|
|
June 24, 2008
|
(Stephen J. Hoffman)
|
|
Directors and Director
|
|
|
|
|
|
|
|
/s/ Paul L. Berns
|
|
President, Chief
Executive Officer
|
|
June 24, 2008
|
(Paul L. Berns)
|
|
and Director
|
|
|
|
|
(Principal Executive
Officer)
|
|
|
|
|
|
|
|
/s/ David C. Clark
|
|
Vice President, Finance
and Treasurer
|
|
June 24, 2008
|
(David C. Clark)
|
|
(Principal Financial
Officer and
|
|
|
|
|
Principal Accounting
Officer)
|
|
|
|
|
|
|
|
/s/ Michael D. Casey
|
|
Director
|
|
June 24, 2008
|
(Michael D. Casey)
|
|
|
|
|
|
|
|
|
|
/s/ Stewart Hen
|
|
Director
|
|
June 24, 2008
|
(Stewart Hen)
|
|
|
|
|
|
|
|
|
|
/s/ Jeffrey R. Latts
|
|
Director
|
|
June 24, 2008
|
(Jeffrey R. Latts)
|
|
|
|
|
|
|
|
|
|
/s/ Jonathan S. Leff
|
|
Director
|
|
June 24, 2008
|
(Jonathan S. Leff)
|
|
|
|
|
|
|
|
|
|
/s/ Timothy P. Lynch
|
|
Director
|
|
June 24, 2008
|
(Timothy P. Lynch)
|
|
|
|
|
3
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024